Q2 and H1 FY27 profit rises sharply on strong revenue growth
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma published unaudited results for the quarter and six months ended September 30, 2026. Consolidated Q2 revenue was Rs 4,337.86 crore, up 17.3% year on year, while profit after tax rose 37.7% to Rs 716.12 crore. For H1, revenue increased 15.2% to Rs 8,368.45 crore and profit after tax rose 33.7% to Rs 1,290.21 crore. Basic EPS was Rs 17.23 versus Rs 12.39 a year earlier.
Strong revenue, profit and EPS growth is positive for shareholders and may support the stock, although the results are unaudited.